Lineage Cell Therapeutics (LCTX) Short Interest Ratio & Short Volume → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free LCTX Stock Alerts $1.08 +0.02 (+1.89%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest Lineage Cell Therapeutics Short Interest DataCurrent Short Volume10,900,000 sharesPrevious Short Volume10,580,000 sharesChange Vs. Previous Month+3.02%Dollar Volume Sold Short$0.00Short Interest Ratio / Days to Cover11.0Last Record DateApril 30, 2024Outstanding Shares188,800,000 sharesPercentage of Shares Shorted5.77%Today's Trading Volume1,361,186 sharesAverage Trading Volume987,104 sharesToday's Volume Vs. Average138% Short Selling Lineage Cell Therapeutics ? Sign up to receive the latest short interest report for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatLCTX Short Interest Over TimeLCTX Days to Cover Over TimeLCTX Percentage of Float Shorted Over Time Ad Allegiance GoldDoes this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit Lineage Cell Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202410,900,000 shares $0.00 +3.0%N/A11 $0.00 4/15/202410,580,000 shares $0.00 +1.7%N/A11.2 $0.00 3/31/202410,400,000 shares $0.00 +4.2%N/A11.4 $0.00 3/15/20249,980,000 shares $0.00 +3.7%N/A11.9 $0.00 2/29/20249,620,000 shares $0.00 -4.2%N/A11.5 $0.00 2/15/202410,040,000 shares $0.00 +18.7%N/A13.1 $0.00 Get the Latest News and Ratings for LCTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20248,460,000 shares $0.00 +7.4%N/A11.3 $0.00 1/15/20247,880,000 shares $0.00 +13.5%N/A12.7 $0.00 12/31/20236,940,000 shares $0.00 +12.9%N/A11.3 $0.00 12/15/20236,150,000 shares $0.00 -3.5%N/A11.9 $0.00 11/30/20236,370,000 shares $0.00 +6.0%N/A13.4 $0.00 11/15/20236,010,000 shares $0.00 -2.3%N/A13.3 $0.00 10/31/20236,150,000 shares $7.01 million -2.5%N/A14.1 $1.14 10/15/20236,310,000 shares $0.00 +1.5%N/A14.2 $0.00 9/30/20236,220,000 shares $0.00 No ChangeN/A13.2 $0.00 9/15/20236,220,000 shares $0.00 +0.7%N/A13.3 $0.00 8/31/20236,180,000 shares $0.00 +1.0%N/A8.1 $0.00 8/15/20236,120,000 shares $0.00 -0.3%N/A7.8 $0.00 7/31/20236,140,000 shares $0.00 -3.6%N/A8.1 $0.00 7/15/20236,370,000 shares $0.00 -1.1%N/A8.6 $0.00 6/30/20236,440,000 shares $0.00 +19.0%N/A9 $0.00 6/15/20235,410,000 shares $0.00 +13.7%N/A7.7 $0.00 5/31/20234,760,000 shares $0.00 +11.5%N/A12.7 $0.00 5/15/20234,270,000 shares $0.00 -6.0%N/A12.8 $0.00 4/30/20234,540,000 shares $0.00 -0.2%N/A12.9 $0.00 4/15/20234,550,000 shares $0.00 +2.9%N/A13 $0.00 3/31/20234,420,000 shares $0.00 +7.3%N/A12.9 $0.00 3/15/20234,120,000 shares $0.00 -1.2%N/A10.9 $0.00 2/28/20234,170,000 shares $0.00 -0.5%N/A11.2 $0.00 2/15/20234,190,000 shares $0.00 +1.0%N/A11.3 $0.00 1/31/20234,150,000 shares $0.00 -0.2%N/A10.5 $0.00 1/15/20234,160,000 shares $0.00 +2.0%N/A10.9 $0.00 12/30/20224,080,000 shares $0.00 -4.0%N/A10.5 $0.00 12/15/20224,250,000 shares $0.00 -1.6%N/A12.5 $0.00 11/30/20224,320,000 shares $0.00 +0.7%N/A13.4 $0.00 11/15/20224,290,000 shares $0.00 -0.2%N/A13.8 $0.00 10/31/20224,300,000 shares $0.00 -3.4%N/A15 $0.00 10/15/20224,450,000 shares $0.00 -0.5%N/A13.9 $0.00 9/30/20224,470,000 shares $0.00 +0.7%N/A14.2 $0.00 9/15/20224,440,000 shares $0.00 -2.8%N/A6.6 $0.00weirdest stock market marches on (Ad)For the last few months, Graham Lindman has been urging investors to ignore virtually every stock on the exchange and only focus on the handful of “Apex Stocks” that produce all the wealth. And he sure seems to be right! Because while we’re in an extremely bullish market, it’s not because most companies are doing that well. It’s because a handful of wealth generating juggernauts are yanking the market to all time highs. That’s why this headline called it the “Weirdest bull market”Graham is hosting a “tell all” workshop about his Apex Indicator here LCTX Short Interest - Frequently Asked Questions What is Lineage Cell Therapeutics' current short interest? Short interest is the volume of Lineage Cell Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 10,900,000 shares of LCTX short. Learn More on Lineage Cell Therapeutics' current short interest. What is a good short interest ratio for Lineage Cell Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LCTX shares currently have a short interest ratio of 11.0. Learn More on Lineage Cell Therapeutics's short interest ratio. Is Lineage Cell Therapeutics' short interest increasing or decreasing? Lineage Cell Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 10,900,000 shares, an increase of 3.0% from the previous total of 10,580,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Lineage Cell Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Lineage Cell Therapeutics: Elevation Oncology, Inc. (11.46%), Fennec Pharmaceuticals Inc (7.82%), Kodiak Sciences Inc. (3.76%), Century Therapeutics, Inc. (5.00%), Adverum Biotechnologies, Inc. (8.04%), INmune Bio, Inc. (13.54%), Genfit S.A. (0.18%), Opthea Limited (0.22%), Compugen Ltd. (2.25%), Innate Pharma S.A. (0.10%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Lineage Cell Therapeutics stock? Short selling LCTX is an investing strategy that aims to generate trading profit from Lineage Cell Therapeutics as its price is falling. LCTX shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Lineage Cell Therapeutics? A short squeeze for Lineage Cell Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of LCTX, which in turn drives the price of the stock up even further. How often is Lineage Cell Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LCTX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: ELEV Short Interest Data FENC Short Interest Data KOD Short Interest Data IPSC Short Interest Data ADVM Short Interest Data INMB Short Interest Data GNFT Short Interest Data OPT Short Interest Data CGEN Short Interest Data IPHA Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSEAMERICAN:LCTX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaUrgent Nvidia WarningAltimetryDems have chosen Biden replacement?Paradigm PressMost important medical advance in 100 yearsThe Oxford ClubNext President (Not Trump. Not Biden.)The Freeport SocietyCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders